Screener
BioMarin Pharmaceuticals BMRN Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
FAQ
- What is BioMarin Pharmaceuticals's interest expense?
- BioMarin Pharmaceuticals (BMRN) reported interest expense of $63.3M in Q2 2026.
- How has BioMarin Pharmaceuticals's interest expense changed year-over-year?
- BioMarin Pharmaceuticals's interest expense increased by 2262.6% year-over-year, from $2.68M to $63.3M.
- What is the long-term trend for BioMarin Pharmaceuticals's interest expense?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's interest expense has grown at a -8.2% compound annual growth rate (CAGR), from $15.34M to $10.9M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about BioMarin Pharmaceuticals's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude